TY  - JOUR
AU  - Martin-Malo, Alejandro
AU  - Borchard, Gerrit
AU  - Flühmann, Beat
AU  - Mori, Claudio
AU  - Silverberg, Donald
AU  - Jankowska, Ewa A
PY  - 2018
DO  - 10.1002/ehf2.12400
UR  - http://hdl.handle.net/10668/13482
T2  - ESC heart failure
AB  - Iron deficiency is the leading cause of anaemia and is highly prevalent in patients with chronic heart failure (CHF). Iron deficiency, with or without anaemia, can be corrected with intravenous (i.v.) iron therapy. In heart failure patients, iron...
LA  - en
PB  - Wiley
KW  - Ferric carboxymaltose
KW  - Heart failure
KW  - Intravenous
KW  - Iron deficiency
KW  - Nanomedicines
KW  - Parenteral
KW  - Administration, intravenous
KW  - Anemia, iron-deficiency
KW  - Ferric compounds
KW  - Global health
KW  - Heart failure
KW  - Humans
KW  - Morbidity
KW  - Quality of life
KW  - Stroke volume
KW  - Survival rate
KW  - Treatment outcome
TI  - Differences between intravenous iron products: focus on treatment of iron deficiency in chronic heart failure patients.
TY  - research article
VL  - 6
ER  -